Novamed News
8 articles
growth-positive
Novamed seeks to make your home your medical lab
Israeli company Novamed, known for developing and marketing laboratory test components, is preparing to launch its at-home testing products globally. Novamed has developed several pioneering products for at-home testing, including streptococcus tests, pregnancy tests, flu tests, and a home-use test for early diagnosis of acute myocardial infarction. The company is also working on developing saliva-based coronavirus testing kits. Novamed aims to reach the developing and developed world markets and increase its revenue. The home testing market is expected to grow, but challenges remain in terms of accuracy and reliability of tests.
CustomersPartnersInvestmentPublic Trading
growth-positive
החברה הישראלית שמתכננת לכבוש את שוק הבדיקות הביתיות
Israeli company Novamed, which has been developing and marketing components for laboratory tests for nearly 30 years, has recently developed several pioneering products in the field of home testing. The company was sold to Simplyuva, a subsidiary of FIMI, last year. As part of the change, founder Emil Katz left the CEO position and will fill roles of invention and development in the company. The company is now led by Elit Man Biton, formerly a senior executive at Teva. Novamed is now working on the development of home testing kits for COVID-19 based on saliva, instead of inserting a swab into the nose.
Management ChangesExpand
growth-positive
Simplivia Healthcare buys diagnostics co Novamed
Simplivia Healthcare Ltd., a drug delivery company, has acquired 70% of diagnostics company Novamed at a valuation of NIS 24 million. The acquisition was facilitated by investment bank Value Base M&A Israel. Simplivia, controlled by FIMI Opportunity Funds, develops and manufactures closed system transfer devices for the safe administration of hazardous drugs. Novamed, an Israeli developer and manufacturer of diagnostic platforms, will benefit from Simplivias marketing channels and expertise in the medical device field. Simplivia plans to continue its rapid internal growth, make strategic acquisitions, develop new technologies, and expand collaborations with research institutes.
Acquisition
UHWI researches COVID-19 pool-testing in partnership with NovaMed Loop Jamaica
growth-positive
BATM wins $31m European ventilators deal
BATM, an Israeli networking solutions and medical laboratory systems provider, has received a $31 million order from a European government for the delivery of 1,000 critical care mechanical ventilators to be used in Intensive Care Units for adults and children with Covid-19. The company has received an upfront fee of €7.25 million and expects the balance to be paid on completion of delivery in the second half of 2020. BATM is also making progress with its Covid-19 diagnostic kits.
CustomersPartners
growth-positive
BATM, Novamed to develop Covid-19 home rapid test kit
BATM has announced a collaboration with Novamed for the joint development and marketing of a Covid-19 rapid testing kit for home use. The kit allows people to test a sputum sample at home and receive results within a few minutes. The companies plan to complete the kits development in 3-4 months and make it available for sale first in Israel and then globally. BATM is also commencing shipment of its new diagnostic kit for Covid-19 developed by Adaltis for use by medical facilities. The initial customers are European, with delivery to Italy being the current focus.
Customers
growth-positive
This Device Can Test For Heart Attacks Before They Happen
Novamed, a startup based in Israel, has developed a device called SensAheart that can predict heart attacks. The device analyzes the presence of certain proteins in a patients blood to indicate the onset of a heart attack. SensAheart aims to detect heart attacks before they happen or while theyre occurring, allowing medical professionals to take necessary measures. The device is currently available in Europe and Israel, and the company plans to expand its availability to the United States. The device is expected to cost less than $30, providing a more affordable option compared to ambulance transportation to the emergency room. The article was published in 2023.
Customers
growth-positive
Home test tip-off to a heart attack
Israeli diagnostic company Novamed has developed SensAheart, a home diagnostics product that can detect a heart attack in progress or before it occurs. The product uses a single drop of blood to test for the presence of troponin and FABP3, markers that indicate a heart attack. Novamed has achieved promising clinical results, with the test giving accurate results for 94% of participants in one study. SensAheart has already been sold in Russia and China, primarily to institutions, but Novamed plans to market it to home users in the future. The company is planning to submit the product for FDA approval and has other projects in development.
CustomersInvestment
